Abstract: The present disclosure belongs to the technical field of soft capsules, and particularly relates to a plant soft capsule and a preparation method and application thereof. The plant soft capsule with excellent performance is prepared from carrageenan, starch, a plasticizer and water by controlling the weight-average molecular weight of the carrageenan to be 1.2×106 to 2.0×106. Compared with a plant soft capsule in the existing technology, the plant soft capsule of the present discourse has lower production cost, and the product quality meets the requirements of gelatin soft capsules; and on the premise of high production efficiency, a low oil leakage rate is achieved, and the rupture time meets United States Pharmacopoeia (USP) standards. The plant soft capsule prepared according to the present disclosure can be filled with an active component as a content and used for preparation of a plurality of drugs, functional food or dietary nutritional supplements.

Abstract: The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.

Abstract: Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, crosslinking the composition and drying the composition. Matrices disclosed herein are useful as wound dressings and treating wounds.

Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Abstract: The present invention aims to provide an aqueous adhesive which has both good moldability and strong adhesive force to the skin, and provides good feeling when used. The present invention can provide an adhesive with good shape retention performance by formulating two or more aqueous macromolecules, polyhydric alcohols, aqueous and insoluble cross-linking agents.

Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: The invention provides medical devices comprising high-strength alloys which degrade over time in the body of a human or animal, at controlled degradation rates, without generating emboli and which have enhanced degradation due to the presence of a halogen component. In one embodiment the alloy is formed into a bone fixation device such as an anchor, screw, plate, support or rod. In another embodiment the alloy is formed into a tissue fastening device such as staple. In yet another embodiment, the alloy is formed into a dental implant or a stent.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.

Abstract: The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

Abstract: A preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent dissolution properties, preferable hardness and high drug content uniformity and a manufacturing method thereof. Acetaminophen has a preset particle size and is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed, manufacturing efficiency can be elevated and the cost for manufacturing is also reduced. Thus, an acetaminophen preparation having improved administrability, for example, a reduced size and a manufacturing method thereof are highly useful.

Abstract: Described herein, a water-soluble personal cleansing product, its uses, methods and kit, preferably a water-soluble facial cleansing product, comprising a water-soluble fibrous structure; wherein the water-soluble fibrous structure comprises a plurality of fibrous elements; wherein the plurality of fibrous elements comprises: one or more fibrous element-forming materials comprising one or more hydroxyl polymers comprising a natural starch and/or a modified starch; wherein the plurality of fibrous elements is substantially free of surfactant; wherein the water-soluble personal cleansing product comprises one or more surfaces wherein the one or more surfaces are coated with an oily composition, wherein the oily composition comprises one or more oil ingredients. Alternatively, the one or more surfaces are coated with a cleansing composition comprising one or more surfactants; and wherein the cleansing composition is substantially free of alkyl sulfate and alkyl ether sulfate type of surfactants.

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: Active agent encapsulated with a protective composite coating is provided. The coating comprises a first hydrophilic water-swellable inner coating comprising a sealant agent combined with a plasticizer to coat particles of the active agent; and a second hydrophobic outer coating comprising a hydrophobic component combined with an enteric polymer and a plasticizer. The composite coating enhances the stability/viability of the active agent during prolonged storage prior to administration, and on exposure to harsh physiological conditions (e.g. gastric environment) following administration to permit enteric delivery of the active agent. A method of preparing the coated active agent is also provided.

Abstract: A method of treating or inhibiting degeneration of a retina of a subject in need thereof comprising administering an effective amount of a compound of metipranolol, or a metabolite thereof, to an organ, a tissue, or the subject, wherein the degeneration of the retina is caused by an ocular disease. In some embodiments, the compound, or a metabolite thereof, is administered topically, orally, or parenterally. In some embodiments, a drug delivery vehicle comprising a dosage of the compound, or the metabolite of, is delivered parenterally via intravitreal injection. In further embodiments, the dosage may range from 0.5 ?g/day-15 ?g/day.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: The present document describes methods and uses of biophotonic compositions which comprise at least one oxidant and at least one chromophore capable of activating the oxidant, in association with a pharmacologically acceptable carrier for use in the treatment of skin and soft tissue wounds that have either or both non-resistant and resistant infections.

Abstract: Disclosed are formulations for oral films and other compositions containing therapeutic agents. The therapeutic agents interfere with succinate/succinate receptor signaling. The films and compositions of the present disclosure can be used to treat periodontal disease.